Mary Cushman Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2022	C-reactive Protein and Racial Differences in Type 2 Diabetes Incidence: The REGARDS Study.
9/2019	Calcium Intake and Serum Calcium Level in Relation to the Risk of Ischemic Stroke: Findings from the REGARDS Study.
7/2016	Trans-ethnic Meta-analysis and Functional Annotation Illuminates the Genetic Architecture of Fasting Glucose and Insulin.
10/2015	Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan.
1/2015	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
6/2009	Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Cushman Research Topics

Disease

110	Stroke (Strokes) 05/2024 - 02/2002
87	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 02/2002
83	Atherosclerosis 07/2022 - 08/2003
66	Inflammation (Inflammations) 12/2024 - 01/2002
51	Venous Thromboembolism 01/2024 - 04/2002
50	Hypertension (High Blood Pressure) 04/2024 - 04/2002
41	Coronary Disease (Coronary Heart Disease) 11/2022 - 08/2003
40	Ischemic Stroke 04/2024 - 07/2003
28	Venous Thrombosis (Deep-Vein Thrombosis) 01/2024 - 01/2002
26	Neoplasms (Cancer) 10/2023 - 12/2002
24	Heart Failure 02/2022 - 05/2003
23	Obesity 12/2020 - 03/2003
20	Thrombosis (Thrombus) 04/2024 - 02/2003
19	COVID-19 11/2023 - 01/2020
18	Chronic Renal Insufficiency 04/2024 - 04/2005
16	Cognitive Dysfunction 01/2024 - 09/2012
16	Myocardial Infarction 01/2023 - 08/2003
12	Hemorrhage 03/2024 - 04/2003
12	Atrial Fibrillation 01/2024 - 02/2002
12	Critical Illness (Critically Ill) 11/2023 - 05/2009
12	Thromboembolism 01/2020 - 12/2002
11	Chronic Kidney Failure (Chronic Renal Failure) 01/2024 - 04/2007
9	Diabetes Mellitus 05/2024 - 05/2007
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2024 - 11/2008
8	Kidney Diseases (Kidney Disease) 10/2022 - 05/2008
7	Thrombophilia 04/2024 - 01/2002
7	Insulin Resistance 01/2021 - 02/2007
7	Peripheral Arterial Disease 01/2019 - 02/2016
7	Vascular Diseases (Vascular Disease) 01/2014 - 01/2004
6	Fibrosis (Cirrhosis) 07/2022 - 10/2018
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2009
6	Activated Protein C Resistance (APC Resistance) 01/2021 - 04/2002
6	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/2015 - 02/2002
5	Dementia (Dementias) 02/2024 - 12/2009
5	Renal Insufficiency (Renal Failure) 05/2023 - 05/2008
5	Dyslipidemias (Dyslipidemia) 10/2022 - 01/2012
5	Heart Diseases (Heart Disease) 01/2019 - 09/2006
4	Albuminuria 01/2024 - 06/2011

Drug/Important Bio-Agent (IBA)

73	C-Reactive ProteinIBA 12/2024 - 12/2002
70	Biomarkers (Surrogate Marker)IBA 12/2024 - 04/2005
43	Interleukin-6 (Interleukin 6)IBA 03/2024 - 08/2004
30	fibrin fragment D (D-dimer)IBA 01/2023 - 01/2002
26	Fibrinogen (Factor I)FDA Link 02/2024 - 12/2002
23	Hormones (Hormone)IBA 01/2021 - 10/2004
20	CreatinineIBA 01/2024 - 02/2002
17	LipidsIBA 04/2024 - 04/2002
17	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2024 - 07/2008
17	AlbuminsIBA 01/2022 - 03/2004
16	Brain Natriuretic Peptide (Natrecor)FDA Link 05/2024 - 09/2010
16	Factor VIII (Coagulation Factor VIII)IBA 04/2024 - 12/2002
16	Hemostatics (Antihemorrhagics)IBA 02/2024 - 01/2002
16	AnticoagulantsIBA 01/2024 - 06/2002
16	Antihypertensive Agents (Antihypertensives)IBA 01/2023 - 11/2005
15	pro-brain natriuretic peptide (1-76)IBA 05/2024 - 11/2012
15	LDL CholesterolIBA 03/2024 - 09/2005
15	Estrogens (Estrogen)FDA Link 02/2016 - 08/2003
14	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2018 - 05/2008
13	Cystatin CIBA 01/2024 - 12/2005
13	Heparin (Liquaemin)FDA LinkGeneric 11/2023 - 05/2009
13	HDL CholesterolIBA 01/2023 - 10/2008
12	CalciumIBA 10/2021 - 05/2007
12	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 01/2002
12	LeptinIBA 03/2018 - 02/2007
11	Warfarin (Coumadin)FDA LinkGeneric 02/2024 - 12/2002
11	Protein CIBA 01/2023 - 04/2002
11	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2023 - 07/2008
11	CholesterolIBA 10/2021 - 05/2004
11	AdiponectinIBA 01/2019 - 02/2007
10	Hemoglobins (Hemoglobin)IBA 10/2023 - 10/2005
10	factor V LeidenIBA 02/2022 - 04/2002
10	ResistinIBA 01/2019 - 07/2011
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2024 - 04/2005
9	AntigensIBA 02/2024 - 04/2002
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2002
9	Insulin (Novolin)FDA Link 07/2016 - 01/2002
8	Natriuretic PeptidesIBA 05/2024 - 02/2014
8	CytokinesIBA 03/2024 - 06/2007
8	HomocysteineIBA 03/2018 - 03/2003
7	Lipoprotein(a)IBA 08/2023 - 02/2016
7	von Willebrand FactorIBA 01/2023 - 12/2002
7	Prothrombin (Factor II)IBA 02/2022 - 04/2002
7	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2021 - 06/2009
7	Blood Coagulation Factors (Coagulation Factor)IBA 01/2021 - 07/2002
7	InterleukinsIBA 01/2019 - 02/2010
7	AdipokinesIBA 09/2015 - 06/2007
6	AntithrombinsIBA 02/2024 - 06/2002
6	ORALIT (ORS)IBA 01/2023 - 01/2007
6	Triglycerides (Triacylglycerol)IBA 01/2023 - 10/2007
6	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2021 - 08/2010
6	Progestins (Progestagens)IBA 02/2016 - 08/2003
6	Estradiol (Delestrogen)FDA LinkGeneric 09/2015 - 08/2003
5	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 02/2024 - 05/2010
5	Vitamin K FDA Link 01/2024 - 04/2002
5	Fibrinolysin FDA Link 01/2021 - 06/2009
5	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2016 - 06/2009
4	Fibrinolytic Agents (Antithrombotic Agents)IBA 03/2024 - 07/2020
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2023 - 01/2022

Therapy/Procedure

39	Therapeutics 03/2024 - 04/2003
6	Hormone Replacement Therapy (Therapy, Hormone Replacement) 11/2018 - 07/2002
5	Secondary Prevention 01/2021 - 05/2013